Armata Pharmaceuticals (ARMP) Equity Average (2014 - 2026)

Armata Pharmaceuticals has disclosed Equity Average across 13 years of filings, most recently posting -$265.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at -$265.1 million, down 420.8% year-over-year; the trailing twelve-month figure through Mar 2026 was -$265.1 million (down 420.8% YoY), and the FY2025 annual result was -$133.3 million, down 232.92% from the prior year.
• Equity Average came in at -$265.1 million for Q1 2026 at Armata Pharmaceuticals, down from -$157.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $57.4 million in Q2 2022 to a low of -$265.1 million in Q1 2026.
• The 5-year median for Equity Average is -$44.3 million (2024), against an average of -$34.6 million.
• Across the five-year window, Equity Average soared 88.77% in 2022 and slumped 1536.64% in 2024, its largest moves.
• Armata Pharmaceuticals' Equity Average stood at $40.8 million in 2022, then tumbled by 154.44% to -$22.2 million in 2023, then plunged by 122.7% to -$49.5 million in 2024, then plunged by 217.38% to -$157.1 million in 2025, then plunged by 68.75% to -$265.1 million in 2026.
• The last three Equity Average figures came in at -$265.1 million (Q1 2026), -$157.1 million (Q4 2025), and -$82.5 million (Q3 2025), per Business Quant data.